Barricaid vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 52)
Barricaid logo

Barricaid

ChallengerHealthcare

Spinal Medical Devices

Barricaid (by Intrinsic Therapeutics) is an FDA-approved bone-anchored annular closure device implanted in 12,000+ patients; CMS raised its ASC reimbursement 46% in 2025; first awake-surgery and endoscopic implantations achieved in 2025.

AI VisibilityBeta
Overall Score
C52
Category Rank
#305 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
48
Perplexity
48
Gemini
54

About

Barricaid is the commercial brand name for the Barricaid Annular Closure Device (ACD), a medical device developed and marketed by Intrinsic Therapeutics, a clinical-stage medical device company. The Barricaid ACD received FDA premarket approval on February 8, 2019. It is designed to treat lumbar disc herniation by sealing tears in the annulus fibrosus — the tough outer layer of spinal discs — following discectomy (the surgical removal of herniated disc material). By closing the annular defect, Barricaid aims to contain remaining disc material, reduce the likelihood of reherniation, and alleviate nerve compression and back pain.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

52
Overall Score
88
#305
Category Rank
#3
78
AI Consensus
78
stable
Trend
stable
48
ChatGPT
83
48
Perplexity
87
54
Gemini
85
52
Claude
90
56
Grok
92

Key Details

Category
Spinal Medical Devices
AI Drug Discovery
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.